Nirvana Life Sciences Inc.
CCSE:NIRVShare Statistics
As of January 31, 2026, Nirvana Life Sciences Inc. has 22.92M shares outstanding.
| Shares Outstanding | 22.92M |
Valuation Ratios
These figures are as of January 31, 2026.
| PB Ratio | -1.25 |
| P/TBV Ratio | -2.26 |
| P/FCF Ratio | -1.82 |
| P/OCF Ratio | -1.82 |
Financial Position
As of January 31, 2026, Nirvana Life Sciences Inc. maintains a current ratio of 0.03, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -20.05, indicating conservative leverage, while an interest coverage ratio of -171.94 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.03 |
| Quick Ratio | 0.03 |
| Debt / Equity | -20.05 |
| Debt / EBITDA | -0.41 |
| Interest Coverage | -171.94 |
Financial Efficiency
These figures cover the twelve months ended January 31, 2026. Return on assets (ROA) is negative at -1,720.07, reflecting losses generated across the asset base.
| Return on Assets (ROA) | -1,720.07 |
Dividends & Yields
These figures cover the twelve months ended January 31, 2026. Free cash flow yield is negative at -55.01: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 64.85, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Nirvana Life Sciences Inc. shareholders.
| Shareholder Yield | 64.85 |
| FCF Yield | -55.01 |
Stock Splits
Nirvana Life Sciences Inc.'s most recent stock split took place on March 24, 2025 with a 10:1 split ratio.
| Last Split Date | 3/24/2025 |
| Split Ratio | 10:1 |
Scores
As of January 31, 2026, Nirvana Life Sciences Inc. has an Altman Z-Score of -722.03, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -722.03 |